Navigation Links
Amgen Highlights Data to Be Presented at American Society of Hematology Annual Meeting
Date:12/2/2010

THOUSAND OAKS, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- Amgen (Nasdaq: AMGN) today announced that it will present data from several key Nplate® (romiplostim) studies at the 52nd Annual Meeting and Exposition of the American Society of Hematology (ASH), Dec. 4-7, 2010, in Orlando, Fla. Results from six studies evaluating Nplate in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP) add to the growing body of data supporting the use of Nplate in this setting, including the final efficacy and safety results from the largest and longest study of Nplate in adult chronic ITP. Amgen will also present data for other marketed products including Neulasta® (pegfilgrastim) and Aranesp® (darbepoetin alfa).

"The complete results from a 5-year open-label extension study of Nplate in the adult chronic ITP setting show that Nplate increases and sustains platelet counts in these patients and that adverse event rates were consistent with those reported in previous studies," said Sean Harper, M.D., senior vice president, Global Development and Chief Medical Officer at Amgen. "This is the largest and longest study of Nplate in this setting, and reinforces the potential of Nplate as a long-term treatment option."

Amgen also announced the expansion of its Neulasta FIRST STEP® Program to its newly established co-pay coupon umbrella program, the Amgen FIRST STEP™ Program for commercially insured patients.  The Amgen FIRST STEP™ Program will feature the Nplate FIRST STEP™ Program and Neulasta FIRST STEP® Programs.  The Amgen FIRST STEP™ Program is significant among oncology commercial co-pay coupon programs, as it is the first program under the medical benefit with no income eligibility requirement. The program is intended to help eligible patients meet their deductible, co-insurance, and/or co-payment r
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Amgen Foundation and Ashokas Changemakers Announce Finalists in Patients
2. Choices
3. Empowerment Competition
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Amgen Foundation Awards $4.5 Million Grant to MLA Partner Schools to Invest in LAs Promise
6. Amgen’s Third Quarter 2010 Revenue Unchanged at $3.8 Billion Versus Prior Year
7. Amgen Announces Webcast of 2010 Third Quarter Financial Results
8. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
9. Amgen Highlights Key Clinical Data to be Presented at European Society for Medical Oncology Congress
10. Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa)
11. Amgen and Pfizer Introduce Psophisticated Style: A Guide to Everyday Style and Psoriasis™ Hosted by Tim Gunn
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... , Nov. 18, 2014  Renova Therapeutics, a ... heart failure and other chronic diseases, announced that ... of directors. The company also completed its third ... New board member brings decades of life ... life sciences executive with more than 30 years ...
(Date:11/18/2014)... Tocagen Inc. today announced that ... free survival at six months for recurrent high grade ... FC, compared to published benchmarks. HGG includes glioblastoma, the ... The data were delivered in an oral presentation at the ... of the Society for Neuro-Oncology (SNO) by Tim ...
(Date:11/17/2014)... CHICAGO, Ill. , Nov. 17, 2014  AbbVie (NYSE: ... Global Healthcare Conference in London on ... president and chief financial officer, will make a formal presentation ... time.) A live audio webcast of the ... at www.abbvieinvestor.com .  An archived edition of the session ...
Breaking Medicine Technology:Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 2Renova Therapeutics welcomes new board member, raises $7.52 million in Series C financing round 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 2Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 3Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 4Interim Data Show Increased Median Overall Survival of Recurrent Brain Cancer Patients Treated with Tocagen's Toca 511 & Toca FC, Compared to Published Benchmarks 5
... Reportlinker.com announces that a new market ... Global Market for Hormonal ... http://www.reportlinker.com/p0512284/Global-Market-for-Hormonal-Contraceptives-and-Infertility-Drugs-2011-2018.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... marketed products and indentifies over 40 R&D ...
... Life Science (DavosLife) has today announced preliminary results of ... delta-tocotrienol (Natural e3) in patients with resectable pancreatic cancer. ... family that have been found by researchers to inhibit ... cells. This clinical trial revealed that Natural e3 was ...
Cached Medicine Technology:Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 2Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 3Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 4Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 5Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 6Reportlinker Adds Global Market for Hormonal Contraceptives and Infertility Drugs, 2011-2018 7DavosLife: Vitamin E Tocotrienol Shows Increased Cancer Cell Apoptosis Without Toxicity in Phase 1 Pancreatic Cancer Trial 2DavosLife: Vitamin E Tocotrienol Shows Increased Cancer Cell Apoptosis Without Toxicity in Phase 1 Pancreatic Cancer Trial 3
(Date:11/18/2014)... November 18, 2014 Sometimes at inopportune ... with print devices like unforeseen error messages or paper ... have time to find another printer and they don’t ... IT department is likely tied up with other mission-critical ... , That’s where Electronic Systems, Inc. (ESI) ...
(Date:11/18/2014)... (PRWEB) November 18, 2014 Recently, Wigsbuy has ... These new models are offered at greatly discounted prices now, ... leading online stores of human hair products, offering many real ... products to the global customers, Wigsbuy uses high quality materials ... and keep up with the trend. , “We are ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, 2014 (HealthDay ... out are more likely to develop heart disease, according to ... a toxic combination of fatigue, irritability and demoralization -- have ... report. "In our increasingly busy lives, we,re just under ... is left unchecked for a period of time, it can ...
(Date:11/18/2014)... Dotinga HealthDay Reporter MONDAY, ... smartphone apps that help them track how many calories they ... who used a popular one after their doctor recommended it ... debunk the idea of using such apps as weight-loss tools. ... their level of motivation varied, the researchers noted, and they ...
(Date:11/17/2014)... Toronto, Canada (PRWEB) November 17, 2014 ... the area’s leading provider of non-medical, in-home senior care, ... yearly flu shot. , Aging typically weakens the immune ... infections such as the flu. This is a greater ... the flu are more prevalent; during last year’s influenza ...
Breaking Medicine News(10 mins):Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2Health News:It Is The Most Wonderful Time To Buy Full Lace Wigs At Wigsbuy.com 2Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 2Health News:Feeling 'Worn Out'? Your Heart May Pay the Price 3Health News:Calorie-Tracking Apps May Not Help You Lose Weight 2Health News:Calorie-Tracking Apps May Not Help You Lose Weight 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Encourages Seniors to Get Annual Flu Shot 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Encourages Seniors to Get Annual Flu Shot 3
... Shengtai Pharmaceutical, Inc. (OTC,Bulletin Board: SGTI) ("Shengtai Pharmaceutical" ... high-quality, pharmaceutical grade,glucose products in China, today reported ... 2007., Second Quarter of Fiscal 2008 ... $25.0 million -- Gross profit rose 91% ...
... treatments for the disease, study suggests , , THURSDAY, Feb. 14 ... cells into mice with hemophilia enables the animals to produce ... hemophilia. , The breakthrough finding may lead the way to ... of the disease, researchers believe. , "We were able to ...
... /PRNewswire-FirstCall/ - NUCRYST,Pharmaceuticals Corp. (NASDAQ: NCST ; TSX: ... 2007. Net loss narrowed to $4.0 million, or 22,cents ... to a net loss,of $10.5 million, or 58 cents ... year. The lower net loss for 2007 is primarily ...
... MONTREAL, Feb. 14 /PRNewswire-FirstCall/ - CryoCath(R) Technologies,Inc., the ... announced financial results for the first quarter, ended,December 31, ... Highlights: - EP Revenue for Q1 2008 ... over Q1 2007. All regions around ...
... people,through the U.S. Agency for International Development (USAID), ... Tajikistan after extreme winter weather,and an energy crisis ... This,funding will help provide fuel, heaters, clothing, household ... USAID partners Save the Children,CARE, and Mercy Corps., ...
... 14 Today, Lung Cancer,Alliance announced that for the ... called for a screening program for veterans at high,risk ... USN, (Ret.), chairman of LCA,s Board of,Directors said today, ... these organizations for speaking out about the number one,cancer ...
Cached Medicine News:Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 2Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 3Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 4Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 5Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 6Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 7Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 8Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 9Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 10Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 11Health News:Shengtai Pharmaceutical, Inc. Reports Strong Second Quarter Results of Fiscal Year 2008 12Health News:Transplanted Liver Lining Cells May Cure Hemophilia 2Health News:NUCRYST Pharmaceuticals announces year-end results 2Health News:NUCRYST Pharmaceuticals announces year-end results 3Health News:NUCRYST Pharmaceuticals announces year-end results 4Health News:NUCRYST Pharmaceuticals announces year-end results 5Health News:NUCRYST Pharmaceuticals announces year-end results 6Health News:NUCRYST Pharmaceuticals announces year-end results 7Health News:NUCRYST Pharmaceuticals announces year-end results 8Health News:NUCRYST Pharmaceuticals announces year-end results 9Health News:NUCRYST Pharmaceuticals announces year-end results 10Health News:NUCRYST Pharmaceuticals announces year-end results 11Health News:NUCRYST Pharmaceuticals announces year-end results 12Health News:CryoCath Announces Fiscal 2008 First Quarter Results 2Health News:CryoCath Announces Fiscal 2008 First Quarter Results 3Health News:CryoCath Announces Fiscal 2008 First Quarter Results 4Health News:CryoCath Announces Fiscal 2008 First Quarter Results 5Health News:CryoCath Announces Fiscal 2008 First Quarter Results 6Health News:CryoCath Announces Fiscal 2008 First Quarter Results 7Health News:CryoCath Announces Fiscal 2008 First Quarter Results 8Health News:CryoCath Announces Fiscal 2008 First Quarter Results 9Health News:CryoCath Announces Fiscal 2008 First Quarter Results 10Health News:CryoCath Announces Fiscal 2008 First Quarter Results 11Health News:Veterans Organizations Call for Lung Cancer Screening 2Health News:Veterans Organizations Call for Lung Cancer Screening 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: